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Abstract 
Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histo-
logic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and 
synaptophysin, and potential secretion of hormones, neurotransmitters, neuromodulators 
and neuropeptides. Nevertheless, despite these common characteristics, NETs differ widely in 
terms of their natural histories: high-grade NETs are clinically aggressive and, like small cell 
lung cancer, which they most closely resemble, tend to respond to cisplatin and etoposide. In 
contrast, low-grade NETs, which as a rule progress and behave indolently, do not. In either 
case, the treatment strategy, apart from potentially curative surgical resection, is very poorly 
defined. This report describes the case of a 28-year-old white male with a diagnosis of high-
grade NET of undetermined primary site metastatic to the lymph nodes, skin and paraspinal 
soft tissues, treated with the experimental anticancer agent RRx-001, in the context of a 
phase II clinical trial called TRIPLE THREAT (NCT02489903); serial sampling of tumor material 
through repeat biopsies demonstrated an intratumoral inflammatory response, including the 
amplification of infiltrating T cells, which correlated with clinical and symptomatic benefit. 
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This case suggests that pseudoprogression or RRx-001-induced enlargement of tumor le-
sions, which has been previously described for several RRx-001-treated patients, is the result 
of tumoral lymphocyte infiltration. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Neuroendocrine tumors (NETs) are rare neoplasms (incidence of 2.48–5.86 per 100,000 
per year [1] with an estimated prevalence of ∼105,000 patients in the United States, making 
it an orphan disease [2]). Despite a similar histology and immunoreactivity for the neuroen-
docrine markers chromogranin A and synaptophysin [3], differences in terms of anatomic 
site of origin (see fig. 1) and clinical behavior characterize this heterogeneous disease. 
Within the spectrum of NETs, on the one hand, are low-grade (G1 or G2) NETs (formerly 
termed carcinoid tumors), which usually follow an indolent clinical course, with a median 
overall survival typically measured in multiple years, and, on the other, are aggressive high-
grade (G3) NETs with a propensity to metastasize and a median overall survival typically 
measured in months [4]. The management of NETs with systemic therapies is controversial 
but the current consensus recommends somatostatin analogues for low- to intermediate-
grade NETs, especially carcinoid tumors [5], and platinum-based doublets for high-grade 
NETs [6] when metastatic lesions are present; effective later-line chemotherapy is uncertain. 
RRx-001 is a hypoxia-selective, systemically nontoxic, pan-epigenetic anticancer agent 
[7–9] with immunostimulatory properties [10] that has previously demonstrated activity in 
NETs [11]; it is currently under investigation in multiple clinical trials, including in combina-
tion with the PD-1 checkpoint inhibitor nivolumab (NCT02518958). The hypothesized 
mechanism of RRx-001-induced pseudoprogressive enlargement of tumor lesions, which has 
been previously observed and reported in several RRx-001-treated patients [7, 12], includ-
ing a previous patient with high-grade neuroendocrine disease [11], is immune infiltration. 
Here, we present the case of a male 28-year-old patient at Walter Reed National Military 
Medical Center with a diagnosis of high-grade NET of undetermined primary site, refractory 
to cisplatin and etoposide, who is currently receiving treatment with RRx-001 in the context 
of an open-label clinical trial called TRIPLE THREAT (NCT02489903). Per the TRIPLE 
THREAT protocol, patients with small cell lung cancer, non-small cell lung cancer and high-
grade NETs (hence the name TRIPLE THREAT) receive once weekly 4 mg RRx-001 co-
infused with autologous blood until progression, followed by re-challenge with the same 
platinum regimen used in first line. This design is intended to investigate the potential of 
RRx-001 to episensitize tumors [13], or, in other words, to epigenetically resensitize them to 
previously effective therapies. Of note, in a role reversal of sorts between the passively com-
pliant patient and actively treating physician, the patient, who is fully engaged in making 
decisions about his care, has unusually insisted on serial multiple-site biopsies during treat-
ment with RRx-001. 
Case Report 
A 28-year-old male veteran with a histologically well-differentiated NET of unknown 
primary that has been classified as high grade due to a Ki-67 proliferation index >20% pre-
viously received 6 cycles of cisplatin/carboplatin as first-line chemotherapy, to which he 
initially responded until aggressive progression was detected on CT scan. At this point, the 
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patient was enrolled on the clinical trial TRIPLE THREAT (NCT02489903) for experimental 
treatment with RRx-001. Approximately 6 weeks after starting RRx-001, the patient pre-
sented with sudden growth acceleration of a pathologic ‘non-target’ cervical lymph node in 
the context of a dramatic symptomatic improvement in terms of appetite and energy levels. 
The ‘growth’ on CT scan (fig. 2) was significant enough (3.05–3.33 cm) to discontinue RRx-
001. 
However, because the sudden nodal enlargement was so at odds with the dramatic clini-
cal improvement, his physician (C.A.C.) opted for a core needle biopsy on the suspicion of 
tumor flare or pseudoprogression. At the insistence of the patient, core needle biopsy was 
also obtained on a retroperitoneal lymph node. Pathologist-read hematoxylin and eosin-
stained histological sections from these core needle biopsies at 6 weeks demonstrated signif-
icantly decreased cellularity and the accumulation of T cells visualized with anti-CD3 anti-
bodies. By 12 weeks, repeat biopsies indicated increased T cell infiltrate as demonstrated on 
the graphs below (fig. 3). The percentage of histologically intact tumor and the percentage of 
necrotic tumor were scored per slide. 
Consistent with the entity of pseudoprogression or reactive tumor enlargement, repeat 
imaging at 4 months (fig. 4) demonstrated lymph node shrinkage from 3.33 to 3.14 cm, cor-
relating with the decreased cellularity observed on core needle biopsy specimens. 
Discussion 
Owing to the rarity and heterogeneity of NETs as well as a dearth of randomized clinical 
trials, treatment guidelines, apart from radical curative surgery, are not well established, 
making it a challenging disease to manage. High-grade NETs have been called ‘extrapulmo-
nary small cell lung cancer’ given their histologic similarity [14], leading to treatment with 
etoposide and cisplatin, one of the standard regimens for small cell lung cancer. However, 
the use of this regimen is limited by associated toxicities as well as the almost inevitable 
development of acquired drug and cross drug resistance. VEGF (e.g., sunitinib, sorafenib and 
bevacizumab) and mTOR (e.g., temsirolimus and everolimus) inhibitors have also been in-
vestigated with some evidence of success in the setting of low- to intermediate-grade NETs, 
e.g., carcinoid [15], but their feasibility in high-grade tumors has not been established. 
Unlike these cytotoxic or molecularly targeted agents, the epigenetic inhibitor RRx-001 
is not associated with any systemic hematological or nonhematological toxicities [7], which 
potentially makes it a very attractive option in a hard-to-treat tumor type like NET, where 
meaningful advances have been few and far between. The data from this highly motivated 
and multiply biopsied patient demonstrates evidence of immune reactivity in the form of T 
cell infiltration. The outcome of this lymphocytic infiltrate was tumor flare or so-called 
pseudoprogression – i.e., disease progression followed by regression – on repeat CT scans, 
similar to the transient enlargement of existing lesions seen with the CTLA-4 inhibitor ipi-
lumumab [16]. This apparent tumor growth suggests the potential to misidentify early imag-
ing of RRx-001 with traditional RECIST criteria as progression, inappropriately resulting in 
early discontinuation of a potentially effective therapy. The RRx-001-mediated increase in 
tumor-infiltrating lymphocytes also suggests a potential synergy with immunotherapies 
such as vaccines, oncolytic viruses, immune checkpoint blockers and costimulatory receptor 
agonists. 
Enrollment in the TRIPLE THREAT trial is ongoing, and histological evaluation of biop-
sies from other patients that provide further evidence of RRx-001-mediated immune in-
volvement will be reported. 
167 
 
Case Rep Oncol 2016;9:164–170 
DOI: 10.1159/000444633 
 
© 2016 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/cro 
Carter et al.: Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially 
Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001 
 
 
 
Statement of Ethics 
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the Walter Reed National Military Medical Center Institutional Review Board. 
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Fig. 1. The percent distribution of NETs based on anatomical location. The gastrointestinal tract, particu-
larly the pancreas, small bowel and appendix, is the primary site of origin of NET, followed by the lungs. 
Up to 15% of the patients present metastases from an unknown primary site. Adapted from Yao et al. [2]. 
 
 
 
Fig. 2. CT scan pretreatment and at 4 weeks demonstrating enlargement of a supraclavicular node (red 
arrow). 
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Fig. 3. Graph plotting relative cellularity, necrosis and T cell infiltrate per 40× high-power field (HPF) 
pretreatment vs. 6 and 12 weeks posttreatment using a customized scoring scale from 0 to 3. Scoring was 
carried out as follows: cellularity by Ki-67 index: 1 = <2%, 2 = 2–20%, 3 = >20%; necrosis: 1 = punctu-
ate/focal, 2 = geographic, 3 = widespread. T cell infiltrate: scoring by number of CD3+ T-cells per 40× HPF. 
LN = Lymph node. 
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Fig. 4. CT scan at 4 weeks and at 8 weeks demonstrating shrinkage of the supraclavicular node (red ar-
row), indicative of pseudoprogression. 
 
